Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Ovarian cancer surgery: does following guidelines save money and improve life quality?

NCT ID NCT02854215

Knowledge-focused Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether following national guidelines for ovarian cancer surgery is cost-effective. Researchers measured the cost per quality-adjusted life year (QALY) over three years in 200 women with advanced ovarian cancer. The goal was to understand the economic impact of guideline adherence, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

200 people

The number who actually took part.

Started

Jan 2017

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * 1\. Woman with age ≥ 18 years. * 2\. Newly diagnosed ovarian, tubal or peritoneal malignancies. * 3\. Epithelial histology. * 4\. Stage IIIC or IVA with extrapelvic carcinomatosis according to FIGO classification 2014. * 5\. Patients undergoing primary surgery or neoadjuvant chemotherapy. * 6\. Performance Status ≤ 2. * 7\. Patient affiliated to a Social Health Insurance in France. * 8\. Patient information and informed consent form signed prior to any study specific procedures. Exclusion Criteria: * 1\. Benign or borderline tumors. * 2\. Patients with extra-abdominal disease, except for pleural effusion with positive cytology. * 3\. Other malignancy diagnosed in the previous 5 years except skin cancer (other than melanoma). * 4\. Any psychological, familial, geographic or social situation, according to the judgment of investigator, potentially preventing the provision of informed consent or compliance to study procedure. * 5\. Patient who has forfeited his/her freedom by administrative or legal award or who is under guardianship.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Fallopian tube cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian cancer primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ovarian cancer

Contacts and locations

Locations

  • Centre Hospitalier Lyon Sud 1

    Pierre-Bénite, 69495, France

  • Centre Hospitalier Lyon Sud 2

    Pierre-Bénite, 69495, France

  • Centre Jean Perrin

    Clermont-Ferrand, 63011, France

  • Chu Clermont Ferrand

    Clermont-Ferrand, 63003, France

  • Hopital Nord-Ouest - Villefranche Sur Saone

    Villefranche-sur-Saône, 69655, France

  • Institut Bergonie

    Bordeaux, 33076, France

  • Institut Claudius Regaud

    Toulouse, 31059, France

  • Institut Curie

    Paris, 75248, France

  • Institut Paoli Calmettes

    Marseille, France

  • Institut Regional Du Cancer Montpellier

    Montpellier, 34298, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.